Results of a phase II trial of the PARP inhibitor, niraparib, in BAP1 and other DNA damage response pathway deficient neoplasms. This is an ASCO Meeting Abstract from the 2022 ASCO Annual Meeting I.
Investopedia contributors come from a range of backgrounds, and over 25 years there have been thousands of expert writers and editors who have contributed. Representative sampling and random sampling ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback